# The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation

> **NCT05732181** · NA · COMPLETED · sponsor: **National Cheng-Kung University Hospital** · enrollment: 154 (actual)

## Conditions studied

- Liver Cancer
- Post Ablation Syndrome

## Interventions

- **DRUG:** The skin lidocaine patch.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05732181
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-09
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732181, "The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05732181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*